You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Investigational Drug Information for Afuresertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Afuresertib?

Afuresertib is an investigational drug.

There have been 13 clinical trials for Afuresertib. The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2012.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Carcinoma, Ovarian Epithelial. The leading clinical trial sponsors are Laekna Limited, Novartis Pharmaceuticals, and GlaxoSmithKline.

Recent Clinical Trials for Afuresertib
TitleSponsorPhase
Human Mass Balance and Biotransformation Study of [14C]AfuresertibLaekna LimitedPhase 1
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1Laekna LimitedPhase 1/Phase 2
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast CancerLaekna LLCPhase 1

See all Afuresertib clinical trials

Clinical Trial Summary for Afuresertib

Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib

See all Afuresertib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.